Alnara Pharmaceuticals primarily focus on developing protein therapeutics. The acquisition of Alnara will provide Lilly with access to the enzyme replacement therapy market.
As it stands, Lilly’s main research area is centred around neuroscience, oncology and diabetes. However, the firm is keen to expand into other therapeutic areas as Lilly’s President of Biomedicines, Bryce Carmine explained. Bryce said the deal “provides Lilly with a promising entry into enzyme replacement therapy, an area with unmet medical needs as well as opportunities for novel compounds that give patients additional treatment options.”
Looking for a job in the pharmaceutical industry? Click here to search our current pharmaceutical jobs online now.